In oral arguments Monday, Merck made its case for federal preemption before the U.S. Supreme Court, saying there was "clear evidence" that the FDA would have rejected language in a warning label proposed for its osteoporosis drug Fosamax.
January 09, 2019 at 02:17 PM
1 minute read
staff reporter
Welcome to Critical Mass, Law.com’s weekly briefing on class actions and mass torts. Here’s what’s happening: Merck made its case for federal preemption before the U.S. Supreme Court. A fee fight has erupted in the Pinnacle hip implant MDL. And find out where Johnson & Johnson will face the first talc trials of 2019.
Send your feedback to [email protected], or find me on Twitter: @abronstadlaw.
Deal Watch: Skadden, Sidley, Slaughter and S&C Lead Big Paper Deal, While Private Funds Grow Massive
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
